A growing body of research is reshaping how scientists understand the relationship between coffee, caffeine, and depression, revealing a complex interaction that may influence both long-term mental health and the effectiveness of advanced depression treatments.
According to the World Health Organization (WHO), 5.7% of adults worldwide — around 332 million people — live with depression. While most respond to standard antidepressant medications, nearly half of all patients experience treatment-resistant depression, requiring advanced therapies such as ketamine and electroconvulsive therapy (ECT).
Psychiatrist Dr Ma-Li Wong, MD, PhD, co-author of Adenosine as the metabolic common path of rapid antidepressant action: The coffee paradox, explains:
“Ketamine and ECT are mainly used when standard antidepressant medications haven’t worked. Almost half of people diagnosed with depression may fall into this category.”
Adenosine surges: The newly uncovered pathway behind rapid antidepressant effects
A breakthrough study published in Nature has identified adenosine signaling as the central biological pathway that drives the rapid antidepressant effects of ketamine and ECT.
Adenosine is a naturally occurring signaling molecule responsible for:
- Dilating blood vessels
- Regulating the sympathetic nervous system
- Lowering blood pressure and heart rate
- Supporting mood regulation
Using genetically encoded sensors and mouse models, researchers found that ketamine triggers a rapid, sustained increase in extracellular adenosine within the medial prefrontal cortex and hippocampus—brain regions strongly linked to depression.
When adenosine receptors were blocked or depleted, ketamine’s antidepressant effects disappeared, confirming adenosine’s crucial role.
They also discovered that acute intermittent hypoxia (aIH)—a noninvasive therapy—produced similar antidepressant effects through adenosine signaling.
Dr Wong emphasized:
“The discovery that adenosine signaling drives the antidepressant effects of ketamine and ECT is a big deal. It opens the door to new treatments that act on adenosine, giving us safer and more scalable ways to help people with depression.”
The caffeine paradox: Can coffee help—or hinder—depression treatment?
A commentary in Brain Medicine explores the so-called coffee paradox:
- Epidemiological studies show that long-term coffee consumption reduces depression risk by up to 25%.
- But caffeine is also an adenosine receptor antagonist, meaning it blocks the very pathway that ketamine and ECT rely on.
Dr Wong warns:
“Caffeine blocks adenosine receptors, and this can interfere with the antidepressant effects of ketamine and ECT—likely in humans as well.”
Why this paradox?
In habitual coffee drinkers, adenosine receptors become upregulated, which may explain the protective effect against long-term depression.
However, acute caffeine use, especially shortly before treatment, may reduce the effectiveness of ketamine, ECT, or aIH.
Should patients avoid caffeine before ketamine or ECT? Experts say yes
Dr Wong recommends avoiding caffeine before treatment:
“It’s sensible to skip coffee or energy drinks for at least 24 hours before ketamine or ECT. Caffeine stays in your system for a long time, and may blunt treatment response.”
However, she notes that more research is needed to determine:
- Whether caffeine affects treatment outcomes in humans
- The ideal caffeine wash-out period before therapy
- Whether personalized metabolics or genetics influence response
- How to design future antidepressants that work synergistically with adenosine pathways
What this means for people with depression
This new evidence highlights several key insights:
- Regular coffee consumption may reduce depression risk over time.
- Caffeine may interfere with rapid-acting antidepressants such as ketamine and ECT.
- Patients undergoing these treatments may benefit from brief caffeine abstinence.
- Adenosine appears to be a central biological target for next-generation antidepressants.
As the science evolves, mental health experts encourage patients to speak with their clinicians before making changes to their caffeine habits.
